Eli Lilly and Co
NYSE:LLY
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
624.2788
1 109.94
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
LLY
stock under the Base Case scenario is
408.77
USD.
Compared to the current market price of 1 038.4 USD,
Eli Lilly and Co
is
Overvalued by 61%.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Eli Lilly and Co.
Fundamental Analysis
LLY Profitability Score
Profitability Due Diligence
Score
LLY Solvency Score
Solvency Due Diligence
Score
Select up to 3 indicators:
Select up to 3 indicators:
Despite the significant buzz around tirzepatide and other diabetes products, their high development and marketing costs could erode profitability if insurance reimbursement or pricing pressures intensify, particularly in today’s cost-conscious healthcare environment.
Eli Lilly’s reliance on blockbuster treatments like Trulicity exposes it to heightened competitive threats and patent cliffs—any new biosimilar entrants or patent challenges could substantially reduce revenue streams faster than anticipated.
R&D setbacks in the high-risk neurology and oncology segments could stall the pipeline’s momentum, especially if trials fail to demonstrate clear clinical benefits, jeopardizing future growth and investor confidence.
Tirzepatide’s rapid approvals and robust clinical outcomes in diabetes and obesity treatments position Eli Lilly to capture valuable market share in a high-growth therapeutic area, protecting long-term revenue streams.
A well-diversified pipeline, including Alzheimer’s candidates like donanemab, aligns with major unmet clinical needs and underscores Eli Lilly’s capacity to deliver innovative treatments that command premium pricing.
The company’s strategic partnerships and acquisitions, such as those aimed at expanding the oncology platform, strengthen its pipeline while distributing R&D risk across multiple promising therapeutic classes.
Revenue & Expenses Breakdown
Eli Lilly and Co
Balance Sheet Decomposition
Eli Lilly and Co
Eli Lilly and Co
Free Cash Flow Analysis
Eli Lilly and Co
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Eli Lilly and Co
Wall St
Price Targets
LLY Price Targets Summary
Eli Lilly and Co
According to Wall Street analysts, the average 1-year price target for
LLY
is 1 129.89 USD
with a low forecast of 713.1 USD and a high forecast of 1 575 USD.
Dividends
Current shareholder yield for
LLY is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
LLY
stock under the Base Case scenario is
408.77
USD.
Compared to the current market price of 1 038.4 USD,
Eli Lilly and Co
is
Overvalued by 61%.